Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥1,489 JPY
Change Today -10.00 / -0.67%
Volume 847.6K
4506 On Other Exchanges
As of 1:00 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

sumitomo dainippon pharma co (4506) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/9/15 - ¥1,625
52 Week Low
12/17/14 - ¥1,132
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SUMITOMO DAINIPPON PHARMA CO (4506)

Related News

No related news articles were found.

sumitomo dainippon pharma co (4506) Related Businessweek News

No Related Businessweek News Found

sumitomo dainippon pharma co (4506) Details

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics, and others in Japan, China, North America, and other regions. The company offers pharmaceutical products, such as therapeutic agents for hypertension, angina pectoris, arrhythmia, Parkinson’s disease, systemic fungal infections, and hepatocellular carcinoma; atypical antipsychotics; rapid-acting insulin secretagogues; vasodilators; and biguanide oral hypoglycemic drugs. It also provides products for therapeutic indications, such as Anderson-Fabry disease, gastroprokines, antiepileptic, sedative hypnotics, short-acting and long-acting beta-agonist, corticosteroid nasal spray, inhaled corticosteroid, carbapenem antibiotics, and serotonin-agonist antianxiety drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, seasonings, and sweeteners; and chemical product materials, such as cosmetic and coating materials, active pharmaceutical ingredients, and electronic chemicals. Further, it provides veterinary medicines for companion animals, including dogs and cats; and farm animals, such as cattle, swine, horses, and cultured fish. Additionally, the company develops point-of-care testing diagnostic products for infectious diseases and acute myocardial infarctions; in-vitro diagnostics for bone and calcium metabolism, and central nervous system disorders; research materials that facilitate research related to medical care; and BBI608 and BBI503 anticancer drug candidates. It has a joint development agreement with Healios K.K. to develop iPS cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration and other eye diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. The company was founded in 1897 and is headquartered in Osaka, Japan.

6,868 Employees
Last Reported Date: 06/19/15
Founded in 1897

sumitomo dainippon pharma co (4506) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sumitomo dainippon pharma co (4506) Key Developments

Sumitomo Dainippon Pharma Co., Ltd. Announces Earnings Results for the First Half Year of 2015; Provides Earnings Guidance for the Year 2016

Sumitomo Dainippon Pharma Co., Ltd. announced earnings results for the first half year of 2015. For the period, the company reported a 11.6% rise year on year net sales to JPY 198.9 billion (USD 1.6 billion), with healthy sales of hypertension drug Aimix (irbesartan + amlodipine) outweighing sluggish sales in long-listed products in Japan. Operating income rose 41% year on year to JPY 16.8 billion, while net income rose 12.4% year on year to JPY 13.2 billion. The company raised its full-year 2016 operating income forecast to JPY 29 billion (the company expected JPY 27 billion previously) and raised its full-year net profit forecast to JPY 20 billion (the company expected JPY 18 billion previously).

Sumitomo Dainippon Pharma Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2015, Payable on December 1, 2015; Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2016

Sumitomo Dainippon Pharma Co., Ltd. announced dividend of JPY 9.00 per share for the second quarter ended September 30, 2015. The dividend is payable on December 1, 2015. The company provided year-end dividend guidance of JPY 9.00 for the fiscal year ending March 31, 2016.

Sumitomo Dainippon Pharma Co., Ltd. Revises Earnings Guidance for the Half Year Ended September 30, 2015

Sumitomo Dainippon Pharma Co., Ltd. revised earnings guidance for the half year ended September 30, 2015. For the period, the company now expects net sales to be ¥198,900 million against previous guidance of ¥197,500 million. Operating income to be ¥16,800 million against previous guidance of ¥11,000 million. Net income attributable to owners of the parent to be ¥13,200 million against previous guidance of ¥8,000 million. Earnings per share to be ¥33.22 against previous guidance of ¥20.14. The net sales are generally as forecasted. SG&A expenses are expected to be lower than the forecast, because, while SG&A expenses less R&D costs are generally as planned, a partial return of the expense is expected in relation to the contingent consideration for SUN-101, a chronic obstructive pulmonary disease therapeutic agent now under development in the U.S. due to reassessment of the fair value, and because some delay is expected in the progress of research and development.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4506:JP ¥1,489.00 JPY -10.00

4506 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $20.04 USD +0.04
Eastman Kodak Co $13.07 USD +0.03
FUJIFILM Holdings Corp ¥5,048 JPY +4.00
GlaxoSmithKline Consumer Nigeria PLC 37.07 NGN 0.00
Pernix Therapeutics Holdings Inc $3.03 USD +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation 4506 Industry Range
Price/Earnings 34.1x
Price/Sales 1.5x
Price/Book 1.3x
Price/Cash Flow 26.2x
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SUMITOMO DAINIPPON PHARMA CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at